A recent study indicates that people who come off popular slimming jabs like Wegovy and Mounjaro may regain lost weight far faster than those who end traditional lifestyle regimens.
Findings released in a major health publication shows that while obese individuals can lose substantial amounts of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Individuals purchasing these drugs should be cognizant of the danger of quick weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight in about one and a half years.
Weighing Approaches
The study, which reviewed 37 of trials involving thousands of patients, compared the outcomes of these new drugs with older methods.
Scientists note that individuals who shed pounds through dieting typically experience a slower creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists believe the mode of action of the injections accounts for the heightened rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the high risk of weight regain, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the chronic character of obesity," akin to managing diseases like hypertension.
User Accounts
People who have stopped the jabs report a intense resurgence of hunger.
"It felt as if a trigger flipping and you become starving," described a patient.
The struggle is compounded if users have not developed permanent lifestyle or habit changes during treatment.
Significant Interest
Survey data show that millions of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits hinges on ongoing lifestyle management.
